Where To Buy Peptides  ·  SS-31 · Safety

SS-31 side effects

SS-31 is one of the few compounds in this market with a real adverse-event list behind it. That list comes from a rare-disease population, and the longest stretch of it covers eight people.

WTBP Research Team Updated 2026-11-16 8 min read 8 cited sources

Most searches for SS-31 side effects hit vendor pages that say "well tolerated" and stop. There is an actual record. It is built on injection site reactions, a failed myopathy trial, and 168 weeks of follow-up in 8 patients.

The short answer. SS-31: Injection site reactions are the most commonly reported adverse event, at roughly 50–70% of treated patients.

SS-31 is elamipretide. The FDA approved it in September 2025. The label covers Barth syndrome only. Injection site reactions are the main reported side effect. Long-term data rests on 8 patients over 168 weeks. Nobody has studied it in healthy adults.

What the SS-31 safety record actually contains

SS-31 is elamipretide. The FDA granted it accelerated approval as Forzinity in September 2025, for Barth syndrome, in patients weighing 30 kg or more. Shirley's 2025 approval review in Drugs sets out that history.

That approval matters for this question. It means a regulator reviewed a safety dataset and an adverse-event list exists. Almost nothing else sold as a research peptide can say that.

The dominant finding is unglamorous. The drug goes under the skin, and the skin objects. Redness, itching, swelling and pain at the injection site are the events reported most often, at rates running around 50–70% of treated patients in the published trials.

Elamipretide was generally well tolerated, with injection site reactions the most commonly reported adverse events.

Stealth BioTherapeutics, TAZPOWER 168-week open-label extension, Genetics in Medicine, 2024

The approval story itself is covered in full on the SS-31 Barth syndrome FDA page.

How big is the safety database?

Smaller than the word "approved" suggests, and that is not a criticism of the drug. Barth syndrome affects roughly 1 in 300,000–400,000 male births. You cannot enroll thousands of people who do not exist.

The wider development program is larger. Across its trials, elamipretide exposure has been reported on the order of 3,500 subjects. But most of that exposure is short, and the longest continuous run on record is the Barth extension.

StudyWhat it ranWhat it adds to safety
TAZPOWER (Barth syndrome)28-week randomized, then open-label to 168 weeksLongest exposure on record, 8 patients
MMPOWER-3 (mitochondrial myopathy)24-week randomizedLargest randomized set; missed both primary endpoints
MMPOWER-3 genotype post hoc (2024)Reanalysis of existing dataNo new exposure; subgroup signal only
Aged mice (Aging Cell, 2025)8 weeks of treatment in old miceNo human safety content at all

Treatment with elamipretide did not meet the primary endpoints of change in 6-minute walk test distance and fatigue score.

Karaa et al., MMPOWER-3, Neurology, 2023

MMPOWER-3 failed on efficacy. It still did the safety work, because a trial that misses its endpoint still counts adverse events. That is the largest controlled block of SS-31 tolerability data anyone has.

What the safety record does not contain

This is the part the vendor pages skip. The known adverse-event profile describes a specific use, in a specific population, for a specific length of time. Step outside that and the record goes quiet.

"Well tolerated in Barth syndrome over 168 weeks in 8 patients" is a true sentence. "Safe" is a different sentence, and nobody has earned it yet.

Is SS-31 safe for anti-aging use?

Unknown. No human trial has given SS-31 to healthy adults for aging, so there is no adverse-event table for that use. Human longevity trials of this compound number zero.

The longevity pitch rests on animals. Mitchell and colleagues published an aged-mouse study in Aging Cell in 2025. Elamipretide improved cardiac and skeletal muscle function in old mice. It did not shift the tissue epigenetic or transcriptomic age markers the authors measured.

That is a functional result in mice, not a safety result in people. The jump from one to the other is the whole marketing argument, and it is unsupported. The mechanism, which runs through cardiolipin in the inner mitochondrial membrane, is set out on the cardiolipin mechanism page, and the broader claim set on the SS-31 benefits page.

Risks that come from the vial, not the molecule

A four-amino-acid peptide in a lyophilized vial carries risks that have nothing to do with the published trials. These are the ones a buyer can actually check.

The full development picture, including what the trials measured and missed, is on the SS-31 complete guide.

What to know now

What we're watching

Stealth BioTherapeutics elamipretide (Forzinity) Barth syndrome approval coverage

Frequently asked questions

What are the most common SS-31 side effects?

Injection site reactions. The drug is given under the skin, and redness, itching, swelling and pain at the site are the events reported most often in the published trials, at rates around 50–70% of treated patients. Systemic events have not dominated the reported tables.

Is SS-31 safe long term?

The longest published continuous human exposure is 168 weeks, in 8 Barth syndrome patients in the TAZPOWER open-label extension. That is the ceiling of the record. Nothing has been published beyond it, so long-term safety past that window is simply unmeasured.

Does SS-31 have side effects in healthy people?

Unknown. Every participant in the trials had a mitochondrial disease. No study has given elamipretide to healthy adults for aging or performance, so there is no adverse-event profile for that use at all.

Did the failed MMPOWER-3 trial raise safety problems?

MMPOWER-3 failed on efficacy, not on safety. Karaa and colleagues reported in Neurology in 2023 that it did not meet its primary endpoints of 6-minute walk distance and fatigue score. A later 2024 post hoc analysis looked at genotype subgroups. The trial still contributed the largest randomized block of tolerability data in the program.

Is a research vial of SS-31 the same as the approved drug?

No. The FDA approved a specific product, made under pharmaceutical manufacturing rules, for one rare disease. A research vial is not that product and carries no approval. Its purity and sterility are only as good as the third-party certificate of analysis that comes with the batch.

References

  1. Shirley, M. (2025). Elamipretide: First Approval. Drugs, 86(3), 377–383. https://doi.org/10.1007/s40265-025-02269-8
  2. Karaa, A., Haas, R., Goldstein, A., Vockley, J., & Cohen, B. (2023). Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial. Neurology. https://doi.org/10.1212/WNL.0000000000207402
  3. Stealth BioTherapeutics. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. https://doi.org/10.1016/j.gim.2024.101138
  4. Karaa, A., Bertini, E., Carelli, V., et al. (2024). Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: A post hoc analysis of the MMPOWER-3 trial. Orphanet Journal of Rare Diseases, 19(1), 431. https://doi.org/10.1186/s13023-024-03421-5
  5. Tung, C., Varzideh, F., Farroni, E., et al. (2025). Elamipretide: A review of its structure, mechanism of action, and therapeutic potential. International Journal of Molecular Sciences, 26(3), 944. https://doi.org/10.3390/ijms26030944
  6. Mitchell, W., Pharaoh, G., Tyshkovskiy, A., et al. (2025). The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell, 24(6), e70026. https://doi.org/10.1111/acel.70026
  7. Clarke, S. L. N., Bowron, A., Gonzalez, I. L., et al. (2013). Barth syndrome. Orphanet Journal of Rare Diseases, 8, 23. https://doi.org/10.1186/1750-1172-8-23
  8. Obi, C., Smith, A. T., Hughes, G. J., & Adeboye, A. A. (2022). Targeting mitochondrial dysfunction with elamipretide. Heart Failure Reviews, 27(5), 1925–1932. https://doi.org/10.1007/s10741-021-10199-2

every peptide, every supplier question, one library.